期刊文献+

辛伐他汀对高胆固醇血症患者血浆内皮素的影响 被引量:5

原文传递
导出
摘要 目的观察辛伐他汀对高胆固醇血症患者血管内皮功能的影响。方法选择高胆固醇血症 (HC) 3 1例 ,口服辛伐他汀 ,分别于治疗前、后进行血管内皮素 (ET)及血脂测定 ;另选 3 0例健康体检者对照。结果辛伐他汀治疗 8周 ,血 TC,低密度脂蛋白 -胆固醇 (LDL -C)明显下降 (P<0 .0 1) ,血浆内皮素由治疗前的 (83 .3 7± 2 6.45 ) pg/ml降至 (5 2 .5 7± 12 .64 ) pg/ml(P<0 .0 1)。结论辛伐他汀在显著降低 HC与 LDL -C的同时 ,能改善血管内皮细胞功能。
出处 《中国综合临床》 北大核心 2001年第10期745-746,共2页 Clinical Medicine of China
  • 相关文献

参考文献5

  • 1Treasure CB,Klein JL,Weintaub WS,et al.Beneficial effects of cholesterol -lowering therapy on the coronary endothelium in patients with coronary artcry diseasc[].The New England Journal of Medicine.1995
  • 2Laufs U,Fata VL,Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[].Circulation.1998
  • 3Arbustini E,Grasso M,Diegoli M,et al.Morphologic changes induced by acetylcholine infusion in normol and atherosclerotic coronary arteries[].The American Journal of Cardiology.1993
  • 4Kaesemeyer WII,Caldwell RB,Huang JZ,et al.Pravastatin sodium activastes endothelial nitric oxide synthase independent of its cholesterol -lowering actions[].Journal of the American College of Cardiology.1999
  • 5O’ Driscoll G,Green D,Taylor RR.Simvastatin, an HMGcoenyme A reductase inhibitor, improvs endothelial function within 1 month[].Circulation.1997

同被引文献33

  • 1王晓燕,潘晓勤,姜新猷.高密度脂蛋白对肾小球系膜细胞损伤的保护作用[J].肾脏病与透析肾移植杂志,1995,4(4):312-314. 被引量:5
  • 2王金泉.肾小球细胞外基质结构、功能的改变与糖尿病肾病[J].肾脏病与透析肾移植杂志,1995,4(3):259-263. 被引量:10
  • 3陈图刚,陈君柱.辛伐他汀对高胆固醇血症患者动脉弹性的影响[J].中国综合临床,2006,22(11):969-970. 被引量:2
  • 4陈娟.丹参酮ⅡA磺酸钠注射液对急性心肌梗死溶栓的干预作用[J].天津药学,2007,19(4):35-36. 被引量:3
  • 5Baker W L, Datta R. Pitavastatin: a new 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor for the treat- ment of hyperlipidemia [ J ]. Adv Ther, 2011,28 ( 1 ) : 13- 27.
  • 6Panchal H J, Suhagia B N, Patel M M, et al. Estimation of pitavastatin calcium in tablet dosage ibrms by column liquid chromatography and ultraviolet spectrophotometry [J].J AOAC Int, 2009,92(1):158-164.
  • 7Suzuki M, Iwasaki H, Fujikawa Y, et al. Synthesis and biological evaluations of quinoline-based HMG-CoA re- ductase inhibitors [ J ]. Bioorg Med Chem, 2001,9 ( 10 ) : 2727 -2743.
  • 8Saito Y. Critical appraisal of the role of pitavastatin in trea- ting dyslipidemias and achieving lipid goals [ J ]- Vase Health Risk Manag, 2009,5:921-936.
  • 9Park S, Kang H J, Rim S J, et al. A randomized, open- label study to evaluate the efficacy and safety of pitavasta- tin compared with simvastatin in Korean patients with hy- percholesterolemia[ J ]. Clin Ther, 2005,27 ( 7 ) : 1074- 1082.
  • 10Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid- lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin [ J ]. Circ J, 2009,73 ( 8 ) : 1466-1472.

引证文献5

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部